Table 1 Baseline characteristics of the patients
Symptomatic SARS-CoV-2 infection | ||||
|---|---|---|---|---|
Overall | Uninfected | Infected | P value* | |
N = 161 | N = 139 | N = 22 | ||
Median age at inclusion (range)—years | 57.7 (21–73.9) | 58 (21–73.9) | 50.3 (29.3–72.7) | 0.18 |
≥ 50 years old—n (%) | 112 (70) | 100 (72) | 12 (55) | |
< 50 years old—n (%) | 49 (30) | 39 (28) | 10 (45) | |
Number of vaccine doses prior to inclusion—n (%) | ||||
4 doses | 19 (12) | 17 (12) | 2 (9.1) | 0.10 |
3 doses | 71 (44) | 61 (44) | 10 (45) | |
2 doses | 22 (14) | 15 (11) | 7 (32) | |
1 dose | 5 (3.1) | 5 (3.6) | 0 (0) | |
0 dose | 44 (27) | 41 (29) | 3 (14) | |
Prior history of SARS-CoV2 infection—n (%)† | 13 (10) | 11 (10) | 2 (11) | > 0.99 |
Median anti-SARS-CoV-2-spike IgG titer (IQR)—BAU/mL† | 16 (1–91) | 16 (1–88) | 15 (4–98) | 0.93 |
Median time between allo-HSCT and inclusion (IQR)—days | 289 (107–552) | 302 (112–560) | 275 (100–529) | 0.80 |
< 12 months—n (%) | 97 (60) | 84 (60) | 13 (59) | 0.90 |
Ongoing immunosuppressive treatment—n (%)† | 100 (62) | 83 (60) | 17 (77) | 0.12 |
History of GvHD requiring systemic treatment—n (%)† | 52 (44) | 46 (45) | 6 (40) | 0.71 |
Median absolute lymphocyte count (IQR)† | 730 (375–1360) | 701 (368–1272) | 1370 (495–1835) | 0.12 |
< 1.0 G/L—n (%) | 81 (60) | 72 (62) | 9 (47) | 0.23 |
Median CD4+ T-cell count (IQR)† | 116 (79–238) | 113 (80–227) | 133 (74–354) | 0.42 |
< 500/mm3—n (%) | 111 (94) | 97 (94) | 14 (93) | > 0.99 |
< 200/mm3—n (%) | 75 (64) | 67 (65) | 8 (53) | 0.38 |
Median CD19+ B-cell count (IQR)† | 15 (0–112) | 33 (0–135) | 0 (0–46) | 0.057 |
< 100/mm3—n (%) | 68 (70) | 55 (66) | 13 (93) | 0.058 |
< 70/mm3—n (%) | 58 (60) | 47 (57) | 11 (79) | 0.12 |
Median gamma-globulin level (IQR)† | 5.6 (4.0–7.3) | 5.6 (3.8–7.2) | 5.8 (4.4–7.3) | 0.67 |
< 7.0 g/L—n (%) | 93 (71) | 81 (72) | 12 (67) | 0.66 |
< 5.0 g/L—n (%) | 47 (36) | 41 (36) | 6 (33) | 0.81 |